Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Gastric cancer ranks the fifth incidence rate among cancers and the second morality cancer following lung cancer. Treatment strategies for gastric cancer are limited to surgical resection and chemotherapy. The cancer organoid model is established from cancer stem cells, with the ability to be self-organized into miniature organs, recapitulating most features of the parental tumor tissue. CAR-T is a promising immunotherapy for gastric cancer treatment. Creative Biolabs offers gastric cancer organoid models-based platforms to measure the efficacy and resistance of targeted CAR-T cells.
We can produce organoids using the basement membrane matrix-based method, air-liquid interface (ALI) method, or using a microfluidic device. The picture shows the main steps for organoid culture.
Fig.1 The procedures for organoids establishment using basement membrane matrix. (Seidlitz, et al., 2021)
Human gastric cancer organoids are assigned to subtypes based on molecular information. at least four kinds of gastric cancer organoids are available for research.
| Subtype | Mutational Features | Histological Features |
| Microsatellite instable subtype (MSI) | MLH1, MSH6, and PIK3CA mutation | Displaying hypermutation phenotype |
| Genomic stable subtype (GS) | PIK3CA, ERBB2, PIK3CA, CDKN2A, frequent CDH1, and RHOA mutations | Displaying diffuse histology |
| Chromosomal instable subtype (CIN) | TP53 mutation, and ERBB2 amplification | Displaying aneuploidy |
| Epstein-Barr virus (EBV) positive subtype | PIK3CA mutations, and CDKN2A silencing |
Organoids are convenient for edition to tissue development, function, and disease. A large biobank of gastric organoids can be used to screen drugs and test responses to therapeutics.
Creative Biolabs has developed multiple high-quality reagents and CAR-T products for immune cell function evaluation using flexible cancer organoids platform.
| Target antigen | Target Description | CAR-T Products |
| Muc3a | Muc3a is a glycoprotein expressed on the cell membrane which belongs to the mucin's family. The abnormal expression of this protein is present in various malignant tumors. | Anti-Muc3a CAR-T |
| EGFR | EGFR is found at abnormally high levels in cancer cells, and EGFR activation appears to be important in tumor growth and progression. | Anti-EGFR CAR-T |
| Mesothelin | Mesothelin (MSLN) is differentially expressed on various solid tumors, such as mesothelioma, ovarian, gastric, pancreatic, and lung cancer. | Anti-Mesothelin CAR-T |
| PSCA | PSCA, prostate stem cell antigen, serving as a biomarker of bladder and prostate cancers, is a proper target for treating gastric cancer using CAR-T cells. | Anti-PSCA CAR-T |
| Claudin18.2 | Claudin18.2 has a high-level expression in gastric, lung, pancreatic, and ovarian cancer and has become a hot medical target for cancer treatment. | Anti-Claudin18.2 CAR-T |
| EpCAM | Epithelial cell adhesion molecule (EpCAM) has an elevated expression in gastric cancer, especially in the metastatic subtype. This transmembrane protein is a target for immunotherapies. | Anti-EpCAM CAR-T |
| CEA | CEA is the short name for carcinoembryonic antigen and has a broad expression in cancer, such as gastric, pancreatic, colorectal, lung, and breast cancer. | Anti-CEA CAR-T |
| NKG2D | NKG2D ligand is present in several gastric cancer-related cell lines. An NKG2D CAR-T is an attractive therapy for targeting NKG2D ligands in tumors. | Anti-NKG2D CAR-T |
| ANTXR1 | Anthrax toxin receptor 1 (ANTXR1), also called endothelial marker 8, is overexpressed in gastric cancer and involves tumorigenesis and development. | Anti-ANTXR1 CAR-T |
| Trop2 | Trop2 is a cell surface protein expressed in tumors of various cancers, including gastric cancer, which helps tumor establishment and metastasis. | Anti-Trop2 CAR-T |
Creative Biolabs offers faster development and enhanced cultures of organoids for CAR-T anti-tumor activity evaluation. Please contact us and get more detailed information.
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
